Pharmaceutical API & Intermediates

Our Pharmaceutical API molecules developed through Biocatalysis

Sitagliptin-Phosphate

Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar.
Sitagliptin was granted FDA approval on October 16, 2006.
Lorven Chemistry team developed a cost effective inhouse developed enzyme bio-catalysis method for improve yields of Sitagliptin -Phosphate.

Pregabalin

Pregabalinis an anticonvulsant drug used to treat neuropathic pain conditions and fibromyalgia, and for the treatment of partial onset seizures in combination with other anticonvulsants.

Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr Lorven Chemistry team developed a cost effective inhouse developed enzyme bio-catalysis method for improved yields of Pregabalin

Atorvastatin-calcium

Atorvastatinis an HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.

Lorven Chemistry team developed a cost effective inhouse developed enzyme bio-catalysis method for improved yields of Atorvastatin-calcium

Leucovorin calcium

Leucovorinis a folate analog used to treat the toxic effects of methotrexate and other folate antagonists, to treat megaloblastic anemia, and to provide palliative treatment of colorectal cancer.

Lorven Chemistry team developed a cost effective inhouse developed catalysis method for improved yields of Leucovorin calcium